RNF43/ZNRF3 loss predisposes to hepatocellular-carcinoma by impairing liver regeneration and altering the liver lipid metabolic ground-state.
Authors
Belenguer, Germán
Arnes-Benito, Robert
Sljukic, Aleksandra
Kakava, Sofia
Davies, Susan
Vacca, Michele
Publication Date
2022-01-17Journal Title
Nat Commun
ISSN
2041-1723
Publisher
Springer Science and Business Media LLC
Volume
13
Issue
1
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Belenguer, G., Mastrogiovanni, G., Pacini, C., Hall, Z., Dowbaj, A. M., Arnes-Benito, R., Sljukic, A., et al. (2022). RNF43/ZNRF3 loss predisposes to hepatocellular-carcinoma by impairing liver regeneration and altering the liver lipid metabolic ground-state.. Nat Commun, 13 (1) https://doi.org/10.1038/s41467-021-27923-z
Abstract
RNF43/ZNRF3 negatively regulate WNT signalling. Both genes are mutated in several types of cancers, however, their contribution to liver disease is unknown. Here we describe that hepatocyte-specific loss of Rnf43/Znrf3 results in steatohepatitis and in increase in unsaturated lipids, in the absence of dietary fat supplementation. Upon injury, Rnf43/Znrf3 deletion results in defective hepatocyte regeneration and liver cancer, caused by an imbalance between differentiation/proliferation. Using hepatocyte-, hepatoblast- and ductal cell-derived organoids we demonstrate that the differentiation defects and lipid alterations are, in part, cell-autonomous. Interestingly, ZNRF3 mutant liver cancer patients present poorer prognosis, altered hepatic lipid metabolism and steatohepatitis/NASH signatures. Our results imply that RNF43/ZNRF3 predispose to liver cancer by controlling the proliferative/differentiation and lipid metabolic state of hepatocytes. Both mechanisms combined facilitate the progression towards malignancy. Our findings might aid on the management of those RNF43/ZNRF3 mutated individuals at risk of developing fatty liver and/or liver cancer.
Keywords
Article, /692/4028/67/1504/1610/4029, /631/67/70, /13/106, /14, /14/19, /38, /38/44, /42, /42/44, /45, /45/91, /59, /64/60, article
Sponsorship
Wellcome Trust (092096/Z/10/Z)
Cancer Research Uk (None)
Wellcome Trust (104151/Z/14/Z)
European Commission (608180)
Identifiers
s41467-021-27923-z, 27923
External DOI: https://doi.org/10.1038/s41467-021-27923-z
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333142
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk